DK3551633T3 - Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere - Google Patents

Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere Download PDF

Info

Publication number
DK3551633T3
DK3551633T3 DK16809388.8T DK16809388T DK3551633T3 DK 3551633 T3 DK3551633 T3 DK 3551633T3 DK 16809388 T DK16809388 T DK 16809388T DK 3551633 T3 DK3551633 T3 DK 3551633T3
Authority
DK
Denmark
Prior art keywords
ones
phosphodiesterase inhibitors
pyrazoloazepin
substituted
substituted pyrazoloazepin
Prior art date
Application number
DK16809388.8T
Other languages
Danish (da)
English (en)
Inventor
Xifu Liang
Jens Larsen
Peter Andersen
Simon Feldbæk Nielsen
Original Assignee
Union Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Therapeutics As filed Critical Union Therapeutics As
Application granted granted Critical
Publication of DK3551633T3 publication Critical patent/DK3551633T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK16809388.8T 2016-12-12 2016-12-12 Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere DK3551633T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/080548 WO2018108230A1 (en) 2016-12-12 2016-12-12 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
DK3551633T3 true DK3551633T3 (da) 2021-06-28

Family

ID=57539258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16809388.8T DK3551633T3 (da) 2016-12-12 2016-12-12 Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere

Country Status (8)

Country Link
US (1) US10906915B2 (cg-RX-API-DMAC7.html)
EP (1) EP3551633B1 (cg-RX-API-DMAC7.html)
JP (1) JP6850886B2 (cg-RX-API-DMAC7.html)
CN (1) CN110088108B (cg-RX-API-DMAC7.html)
DK (1) DK3551633T3 (cg-RX-API-DMAC7.html)
ES (1) ES2875128T3 (cg-RX-API-DMAC7.html)
RU (1) RU2762279C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018108230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11065257B2 (en) * 2016-12-12 2021-07-20 Leo Pharma A/S Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
AU2018286964B2 (en) 2017-06-20 2022-04-14 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2019115776A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803299B1 (fr) * 2000-01-05 2004-09-17 Warner Lambert Co NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7423031B2 (en) 2003-05-01 2008-09-09 Irm Llc Compounds and compositions as protein kinase inhibitors
AR058071A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas.
CA2669886A1 (en) 2006-11-15 2008-05-22 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
PL2114951T3 (pl) * 2007-02-28 2014-10-31 Leo Pharma As Nowe inhibitory fosfodiesterazy
GB0704652D0 (en) 2007-03-09 2007-04-18 Syngenta Participations Ag Novel herbicides
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos

Also Published As

Publication number Publication date
RU2019121006A3 (cg-RX-API-DMAC7.html) 2021-01-12
US10906915B2 (en) 2021-02-02
ES2875128T3 (es) 2021-11-08
US20200010477A1 (en) 2020-01-09
JP6850886B2 (ja) 2021-03-31
EP3551633A1 (en) 2019-10-16
CN110088108B (zh) 2024-06-14
JP2020500920A (ja) 2020-01-16
EP3551633B1 (en) 2021-03-31
WO2018108230A1 (en) 2018-06-21
RU2762279C2 (ru) 2021-12-17
CN110088108A (zh) 2019-08-02
RU2019121006A (ru) 2021-01-12

Similar Documents

Publication Publication Date Title
IL269196A (en) Novel inhibitors
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
IL263586A (en) Inhibitors of the menin-mll interaction
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3442972T3 (da) Bromdomænehæmmere
DK3310784T3 (da) Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
DK3663290T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3233863T3 (da) Kondenserede ringheteroarylforbindelser og anvendelse deraf som trk-hæmmere
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3341379T3 (da) EZH2-hæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3724196T3 (da) Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
EP3600301A4 (en) KDM4 INHIBITORS
EP3615525C0 (en) PYRROLE DERIVATIVES AS PLK1 INHIBITORS